Therapies Chart

As of 2020, there are 3 FDA-approved therapies now available to the NMOSD community. The Sumaira Foundation for NMO is please to share the first-of-its-kind, NMOSD Therapies Chart.

Our goal in laying out these new and available therapies side-by-side is to empower the patient community to discuss their treatment options with their doctors to make informed decisions about their best paths forward. At TSF, we’re strong advocates for shared-decision making between patients and their physicians, especially when it comes to deciding what long-term treatment(s) to opt for.

This chart has been created by TSF. Our foundation works with all three pharmaceutical companies equally with an unbiased and objective lens.

Special thanks to Dr. Michael Levy (subject-matter expert), Andrea Sydney (volunteer project manager), and 3Dcubed (animator) for their support in bringing this chart to fruition.

Legend:

– Animated video for explanation
– Definition in text and audio format

Soliris Logo
Soliris® (eculizumab)
Uplizna logo
Uplizna™ (inebulizumab-cdon)
Enspryng Logo
Enspryng® (satralizumab)
Pharmacology Complement Inhibitor B Cell Depletion Interleuken-6 (IL-6) Inhibitor
Drug Delivery Method Infusion (35 minutes)Infusion (90 minutes)Subcutaneous Injection
Frequency Every 2 weeksEvery 6 monthsEvery 4 weeks
Dosage 1200 mg300 mg120 mg
Reduction in Relapse Risk 94%77% 79% with background therapy,
74% without background therapy
Antibody Criteria AQP4+ (MOG untested) AQP4+ (MOG untested) AQP4+ (MOG untested)
Common Side EffectsHeadaches
Runny Nose
Urinary Tract Infection
Joint Pain
Headaches
Runny Nose
Severe Events (rare)Meningococcus MeningitisNeutropenia
Low lgG
Neutropenia
Elevated Cholesterol
Vaccinations MeningococcusNoneNone
ManufacturerAlexion LogoVielaBIO LogoGenentech Logo
Copay Assistance ProgramsOneSourceViela VIPEnspryng Co-Pay Program